The Japan Times CENTER (0.0) Reliability: 7.5/10

Novo's board bust-up to sharpen drugmaker's focus on U.S. consumers

✍️ Maggie Fick, Bhanvi Satija, Maggie Fick Bhanvi Satija 📅 October 22, 2025 12:00 AM 🕐 Scraped: October 22, 2025

Summary: The Danish drugmaker that initially soared on the success of its obesity drug has lost its market lead to U.S. rival Eli Lilly and cheaper copycats.

Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to be

📰

Continue Reading on The Japan Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Maggie Fick, Bhanvi Satija, Maggie Fick Bhanvi Satija

Original Publisher

🌍 The Japan Times

CENTER Bias (0.0)

Published Date

October 22, 2025 at 12:00 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.

Desktop Only